Core Viewpoint - Titan Technology (688133) has seen a stock price increase of 8.73% this week, closing at 27.4 yuan, with a total market capitalization of 4.506 billion yuan [1] Company Announcement Summary - Titan Technology plans to acquire 100% equity of Apollo Scientific Ltd. (ASL) for approximately 55.85 million yuan to expand its overseas sales channels [1] - The acquisition involves a payment of 5,756,429 GBP, which is about 55.85 million yuan, and is not classified as a related party transaction or a major asset restructuring [1] - ASL reported a revenue of 87.09 million yuan and a net loss of 5.5 million yuan for the year 2024 [1] - The transaction is subject to approval from relevant national and local authorities and will be included in the company's consolidated financial statements upon completion [1] - The acquisition is expected to enhance the company's core competitiveness and diversify its product line [1]

Core Viewpoint - Shanghai Titan Technology Co., Ltd. announced the acquisition of 100% equity in Apollo Scientific Ltd. for £5,756,429, approximately RMB 55.85 million, aiming to enhance its international presence and product offerings [1][2]. Group 1 - The acquisition will allow Titan to expand its overseas channels and enrich its product line [2]. - Apollo Scientific Ltd. specializes in manufacturing and supplying aromatic, heterocyclic, and aliphatic compounds, including fluorinated compounds and life science reagents [1][2]. - The company is known for its high-quality products, inventory levels, rapid delivery times, and exceptional customer service, supporting clients at every stage of the R&D process [1][2]. Group 2 - Apollo Scientific was established in 1993 and has gradually expanded its business through sales and marketing for small international manufacturers in the UK and Europe [2]. - The transaction is expected to improve supply chain efficiency and profitability through synergies [2].

Group 1 - Titan Technology plans to acquire 100% of Apollo Scientific Ltd. for approximately 55.85 million yuan, enhancing its global supply chain and competitiveness in the reagent field [1] - Qianjin Pharmaceutical has received registration certificates for two drugs, enriching its product line and strengthening its position in the treatment of vitamin B12 deficiency and heart failure [2] - Meizhong Jiahe intends to raise approximately 270 million HKD through a share placement, focusing on hospital construction, medical AI, and operational funding [3] Group 2 - ST Weiming has successfully recovered 100% equity of Xiamen Weiming, resolving long-standing equity disputes and stabilizing corporate governance [4] - Guangji Pharmaceutical has been fined 1.5 million yuan for information disclosure violations, highlighting governance issues and the need for compliance to restore investor confidence [5]

Group 1 - Rongzhi Rixin expects a net profit increase of 2,027.62% to 2,179.59% for the first half of 2025, with projected profits between 14 million to 15 million yuan [1] - The significant profit growth is attributed to the acceleration of digital and intelligent transformation across industries, leading to increased revenue from sectors like wind power and petrochemicals [1] - The company has improved operational management efficiency, resulting in enhanced gross margins and overall profitability [1] Group 2 - Jinzhai Food plans to repurchase shares worth between 50 million to 100 million yuan, with a maximum repurchase price of 16 yuan per share [2] - The repurchase will be funded through self-owned funds and a special loan from China Merchants Bank, with a loan commitment of up to 90 million yuan [2] Group 3 - Zhongfu Information's chairman and general manager, Wei Dongxiao, has been detained, and the board has arranged for the deputy general manager to assume his responsibilities during this period [3][4] - The company states that this situation will not significantly impact its daily operations [4] Group 4 - Shenzhen Energy plans to invest approximately 789.703 million yuan in the construction of the Honghaiwan offshore wind power project, with a portion funded through financing [6] - The company will increase its capital in its subsidiary by 153.108 million yuan to support this project [6] Group 5 - *ST Zitian faces potential delisting due to failure to rectify false financial reporting as mandated by the China Securities Regulatory Commission [8] - The company has not disclosed corrected financial reports within the required timeframe, leading to a warning of delisting risk [8] Group 6 - Watson Bio has signed a strategic cooperation framework agreement with Yuxi State-owned Capital Operation Co., aiming to establish a long-term partnership in the vaccine and bioproducts industry [10] - The collaboration is expected to enhance innovation and business expansion in the vaccine sector [10] Group 7 - Weiming Environmental reported a total power generation of 226,162.29 million kWh in the first half of 2025, representing a year-on-year increase of 7.54% [12] - The company also recorded a total waste input of 689.32 million tons, with a growth of 8.71% compared to the previous year [12]

Group 1 - Industrial and Commercial Bank of China plans to redeem $2.9 billion of overseas preferred shares, with the redemption scheduled for September 23, 2025 [1] - Everbright Bank's stake held by CITIC Financial Asset Management increased from 7.08% to 8% after acquiring 264 million A-shares and 279 million H-shares [1] - Weiming Environmental reported a 7.54% year-on-year increase in electricity generation, totaling 2.262 billion kWh in the first half of 2025 [1] Group 2 - Tiancheng Automation announced that Yunnan Trust plans to reduce its stake by up to 1%, equating to a maximum of 3.971 million shares [2] - Baobian Electric revealed that the Equipment Finance Group intends to reduce its stake by up to 1%, or 18.4153 million shares [3] Group 3 - Titan Technology plans to acquire 100% of Apollo Scientific Ltd. for approximately 55.85 million yuan to expand its overseas sales channels [4] - China Communication Signal announced winning seven significant projects in the rail transit market, with a total bid amount of approximately 1.431 billion yuan [5] Group 4 - Rongzhi Rixin expects a net profit increase of 2027.62% to 21.7959 million yuan for the first half of 2025, driven by digital and intelligent transformation in various industries [6] Group 5 - Sanmu Group is facing three lawsuits from Fuzhou Rongtou over a sales contract dispute, with the total amount in question being approximately 107 million yuan [8] - Sanfu Outdoor received approval from the China Securities Regulatory Commission for a specific stock issuance [8] - Jin Zai Foods plans to repurchase shares worth between 50 million and 100 million yuan for employee incentive plans [8] - Supor reported a slight decline in net profit to 940 million yuan for the first half of 2025, despite a revenue increase of 4.68% [8] Group 6 - Watson Bio signed a strategic cooperation framework agreement with Yuxi State-owned Capital Operation Company to enhance collaboration in the vaccine and bioproducts industry [9] - Qidi Design, as the lead of a consortium, won a bid for the Henan Airport Intelligent Computing Center project, with a construction bid of 860 million yuan [10] Group 7 - Nantian Information plans to sign a procurement framework contract worth 58.27 million yuan with its controlling shareholder [11] - Matrix Co. reported new orders worth 272 million yuan in the second quarter for its decoration business, with total uncompleted orders amounting to 677 million yuan [12] - Beixin Road and Bridge's subsidiaries won contracts totaling 1.629 billion yuan for highway projects, which could positively impact future performance [12]

Core Viewpoint - Shanghai Titan Technology Co., Ltd. plans to acquire 100% equity of Apollo Scientific Ltd. from Central Glass Japan for £5,756,429, aiming to enhance its international presence and core competitiveness [1][2][3]. Group 1: Investment Overview - The company intends to use its own or self-raised funds for the acquisition, which is not classified as a related party transaction or a major asset restructuring [1][4]. - The transaction is part of the company's strategic plan to expand overseas sales channels and accelerate internationalization [2][3]. Group 2: Transaction Details - The acquisition will result in Apollo Scientific Ltd. being included in the company's consolidated financial statements as a subsidiary [3]. - The transaction is subject to approval from relevant national and local authorities, and the company has authorized its management to handle the necessary procedures [4][5]. Group 3: Target Company Information - Apollo Scientific Ltd. is a private limited company registered in England, primarily engaged in the distribution and customized services of chemical products [6][7]. - The financial performance of Apollo Scientific Ltd. shows a revenue of £8.71 million in 2024 and a net loss of £0.55 million, with total assets of £11.55 million and total liabilities of £0.96 million [7][8]. Group 4: Strategic Benefits - The acquisition is expected to enhance the company's sales and warehousing systems, facilitating faster responses to overseas customer demands and expanding its global reach [3][8]. - The integration of Apollo Scientific Ltd. is anticipated to improve procurement channels and optimize costs, thereby enhancing profitability [3][8]. Group 5: Due Diligence and Valuation - The company has engaged professional institutions for legal and financial due diligence, ensuring compliance and risk assessment related to the transaction [8][9]. - The purchase price was determined based on the target company's net assets and potential business synergies, amounting to £5,756,429 (approximately ¥55.85 million) [8][9].

证券代码：688133 证券简称：泰坦科技 公告编号：2025-029 上海泰坦科技股份有限公司 关于拟收购境外公司股权并签署股权收购协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 对外投资概况：上海泰坦科技股份有限公司（以下简称"公司"）拟使 用自有或自筹资金 5,756,429 英镑（以 2025 年 7 月 23 日汇率折合人民币约 5,585 万元）收购中央硝子株式会社（即 Central Glass Co., Ltd，东京证券交 易所上市公司，股票代码 4044，以下简称"Central Glass 日本"）持有的 Apollo Scientific Ltd.（英格兰注册的私人股份有限公司，以下简称"标的公 司"或"ASL"） 100%的股权。（以下简称"本次交易"） 本次交易涉及境外投资，相关股权和资产的交割须符合所在地区法律规定和 监管部门要求。 其它需要提醒投资者重点关注的风险事项： 由于交易架构复杂，交易双方分别为中国和日本证券交易所上市的企业，交 易标的涉及全球多地的法律、财 ...

Core Viewpoint - Titan Technology plans to acquire 100% of Apollo Scientific Ltd. (ASL) from Central Glass Japan for £5.7564 million (approximately 55.85 million RMB) to enhance its international presence and competitiveness in the chemical distribution sector [1] Group 1: Acquisition Details - The acquisition will make ASL a subsidiary of Titan Technology, included in its consolidated financial statements [1] - ASL specializes in the supply of chemicals and related products, focusing on distribution and customized services [1] Group 2: Strategic Objectives - The transaction aims to expand overseas sales channels and improve the company's international layout [1] - The acquisition is part of Titan Technology's strategy to accelerate its internationalization process and enhance core competitiveness [1] Group 3: Regulatory Requirements - The transaction is subject to approval and filing with relevant national and local authorities [1]

中信证券股份有限公司 关于上海泰坦科技股份有限公司 使用部分闲置募集资金暂时补充流动资金之核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为上海 泰坦科技股份有限公司（以下简称"泰坦科技"或"公司"）2021 年度向特定 对象发行股票的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券 交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》《上市公司募集资金监管规则》等有关法律法规和规范性文 件的要求，对泰坦科技拟使用部分闲置的 2021 年度向特定对象发行 A 股股票募 集资金暂时补充流动资金的事项进行了认真、审慎的核查，发表如下意见： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意上海泰坦科技股份有限公司向特定 对象发行股票注册的批复》（证监许可〔2022〕871 号），上海泰坦科技股份有 限公司向特定对象发行 A 股股票 7,624,896 股，发行价格为人民币 131.61 元/股， 本次发行的募集资金总额为人民币 1,003,512,562.56 元，扣除相关发行费用人民 币 18,328,561.10 元，募集资金净额为 ...

重要内容提示： 证券代码：688133 证券简称：泰坦科技 公告编号：2025-028 上海泰坦科技股份有限公司 关于使用部分闲置募集资金暂时补充流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 截至 2025 年 5 月 30 日，上海泰坦科技股份有限公司（以下简称"公司" "泰坦科技"）已提前将于 2025 年 6 月 13 日到期的前次用于暂时补充流动资金 的 15,000 万元提前全部归还至募集资金专用账户，并将上述募集资金的归还情况 通知了公司的保荐机构及保荐代表人； 2025 年 6 月 27 日，公司召开了第四届董事会第十六次会议、第四届监 事会第十五次会议，审议通过了《关于使用部分闲置募集资金暂时补充流动资金 的议案》。根据募集资金投资项目的资金使用计划及项目的建设进度，在确保不 影响募集资金投资项目建设进度的前提下，为提高募集资金使用效率，减少公司 财务费用，降低公司运营成本，公司拟使用额度不超过人民币 15,000.00 万元 （含本数）的闲置的 2021 年度向特定对象发行 A 股股票募 ...